Language:
Instant News and Commentaries
2024-03-02
18:14
中國重汽加速邁向世界一流科技強企

濟南2024年3月2日 /美通社/ -- 3月2日,中國重汽2024年度科技創新獎勵大會隆重召開,表彰獎勵2022年以來的重大科技成果和傑出創新人才,安排部署今後一段時期的科技創新工作。山東重工集團董事長、總經理,中國重汽集團董事長譚旭光出席大會,作《腳踏實地迎接科技巨變》科技創新工作報告。

5年來,中國重汽累計研發投入近150億元,是前15年的總和,對標世界一流,逐步搭建起全流程自主研發體系,中國重汽的科技硬實力已經走到全國行業的前列;中國重汽以科技重塑「黃河」重卡、躍居中國第一,高科技指標全面引領行業;重卡市占率從2018年的16.5%提升至2023年的26%,連續兩年中國第一;2023年出口銷量首次突破13萬輛,較5年前增長2.6倍,單一品牌全球出口銷量最大。

譚旭光號召全體工程師,要牢記囑托,腳踏實地、執著創新,在十年磨劍的堅守中久久為功,在全球合作中汲取智慧,在項目磨礪中成長成才,要在源源不斷的價值創造中,實現人生價值,用無限的青春活力、無悔的青春奮鬥、無畏的青春熱血,向著百年重汽、世界重汽再出發!

Information Provided by PR Newswire [Disclaimer]
18:05
Sinotruk leaping forward to become world-class technology enterprise

JINAN, China, March 2, 2024 /PRNewswire/ -- On March 2, SinoTruk's Science and Technology Innovation Award Annual Conference 2024 was grandly held, to recognize and rewarding major scientific and technological achievements and outstanding innovative talents since 2022, planning and deploying scientific and technological innovation work ahead. Tan Xuguang, Chairman and General Manager of Shandong Heavy Industry Group, Chairman of China National Heavy Duty Truck Group, attended the conference and delivered a report on scientific and technological innovative work - "Steadily stride forward, embracing change in science and technology".

Over the past five years, Sinotruk has invested nearly RMB 15 billion in R&D, which is the sum of the previous 15 years. It has benchmarked against world-class standards and gradually established a full-process independent research and development system. Sinotruk technological strength has reached the forefront of the national industry. Sinotruk has reshaped the "Yellow River" heavy-duty trucks standard with technology, ranking first in China, and its high-tech indicators are leading the industry. The market share of heavy-duty trucks has increased from 16.5% in 2018 to 26% in 2023, ranking first in China for two consecutive years. In 2023, the export volume exceeded 130,000 vehicles for the very first time, a 2.6-fold increase compared to 5 years ago, making it the largest single-brand global export volume in the world.

Tan Xuguang called on all engineers to keep in mind their mission, be down-to-earth, persistent in innovation, and make long-term achievements through dedicated ten years of hard work. Learn from the global cooperation, grow and become talents through project training, and achieve through continuous value creation. Achieve your meaning in life, strive with vitality and passion while you are young. Let's set off again for a better future for the century heavy truck industry and the world's best heavy truck industry!

Information Provided by PR Newswire [Disclaimer]
2024-03-01
20:45
再創紀錄 中國重汽2月重卡出口突破14000輛!

中國濟南2024年3月1日 /美通社/ -- 3月1日上午,「中國重汽 與世界共贏」——中國重汽2024年2月出口第14000輛重卡發車儀式在濟南綜合保稅區隆重舉辦。山東重工集團董事長,中國重汽集團董事長,濰柴集團董事長譚旭光出席活動並講話。

上午10時,50輛中國重汽重卡在汕德卡C7H的引領下依次駛出濟南綜合保稅區大門,標誌著中國重汽重卡單月出口成功突破14000輛,再次刷新了由自己保持的中國重卡企業出口的單月最高紀錄,樹立起中國重型卡車行業出口新的里程碑。

剛剛過去的2023年,中國重汽營業收入同比增長44%,利潤同比增長191%,連續兩年問鼎中國重卡銷售第一名。其中其中,重卡出口全年實現13萬輛,同比增長47%,創造了歷史最好紀錄,成為全球單一品牌重卡銷量第一。

截至目前,中國重汽在全球90多個國家發展各級經銷網點約300家,在全球110多個國家建立了近600個服務網點和配件網點,助力全球各地的物流體系建設,向全世界展示出中國品牌的強大實力。

此次中國重汽單月海外出口重卡突破1.4萬輛,是山東重工集團邁向全球的一個縮影。今年前兩個月,山東重工集團出口收入達到154億元,同比增長27%,旗下中國重汽、陝汽重卡、濰柴集團、山推股份、中通客車等企業產品出口均取得歷史性突破。其中,中通客車出口同比增長201%,挖掘機出口同比增長87%,農業裝備出口同比增長47%,海外出口業務全面開花,國際化進程全面提速。

Information Provided by PR Newswire [Disclaimer]
20:44
Record high - Sinotruk Heavy Truck exported more than 14,000 vehicles in Feb 2024.

JINAN, China, March 1, 2024 /PRNewswire/ -- On March 1, "Sinotruk wins together with the world" - the launch ceremony of Sinotruck's 14,000th heavy truck exported in February 2024 was held in Jinan Comprehensive Bonded Zone. Tan Xuguang, Chairman and General manager of Shandong Heavy Industry Group and Chairman of Weichai Power delivered a speech officiating the event.


At 10 a.m., 50 Sinotruk heavy trucks drove out of the gate of Jinan Comprehensive Bonded Zone in proper sequence under the guidance of SITRAK C7H. It signified that Sinotruk successfully exported more than 14,000 units in a single month, once again, breaking its own highest single-month export record for Chinese heavy truck companies and setting a new milestone.

In the year 2023, Sinotruk operating income increased by 44% year-on-year, and its profits increased by 191% year-on-year. It has ranked first in China's heavy-duty truck sales for two consecutive years. Among them, heavy truck exports reached 130,000 units throughout the year, a year-on-year increase of 47%, setting the best record in history and becoming the world's number one single-brand heavy truck sales volume.

Up till now, Sinotruk has developed approximately 300 distribution outlets at all levels in more than 90 countries around the world, and has established nearly 600 service outlets and parts outlets in more than 110 countries, facilitating the construction of logistics systems and showcased the most powerful strength of Chinese brands to the world.

By the time, Sinotruk's overseas exports of heavy trucks exceeded 14,000 units in a single month, which is a microcosm of Shandong Heavy Industry Group's global expansion.

In the first two months of this year, Shandong Heavy Industry Group's export revenue reached 15.4 billion yuan, a year-on-year increase of 27%. The export products of its subsidiaries such as Sinotruk, Shaanxi Heavy Duty Automobile, Weichai Group, Shantui Construction Machinery and Zhongtong Bus all achieved historical breakthroughs. Among them, Zhongtong bus exports increased by 201% year-on-year, excavator exports increased by 87% year-on-year, and agricultural equipment exports increased by 47% year-on-year. Overseas export business has fully blossomed, and the internationalization process has accelerated.

Information Provided by PR Newswire [Disclaimer]
14:08
武鋼有限、中國聯通和中興通訊榮獲 GSMA GLOMO 「 最佳互聯經濟移動創新獎」

西班牙巴塞羅那2024年3月1日 /美通社/ -- 在MWC24巴塞羅那上,由寶鋼股份武漢鋼鐵有限公司(簡稱 武鋼有限 )、中國聯通和中興通訊聯合打造的 5G全連接智慧鋼鐵工廠 項目榮獲GSMA全球移動大獎(GLOMO)— 最佳互聯經濟移動創新獎 (Best Mobile Innovation for Connected Economy)。

武鋼有限 智慧鋼鐵工廠 項目目前已建成全球鋼鐵行業最大的5G專網,在園區實現99%的5G覆蓋,並基於5G專網部署了6大類25個鋼鐵應用場景,貫通智慧物流、生產管控、數字設備、能環管控、質量管控、安全管控等全流程,建成一個公司級管控中心和煉鐵、煉鋼、CSP、熱軋四大廠區操控中心,實現一鍵式煉鋼。

5G專網已應用於武鋼有限的核心生產領域,實施無人化改造的行車已超過100個。智慧鐵水運輸實施以來,運輸效率不斷提升,TPC鐵水溫降歷史性突破100°C,創造鐵鋼界面極致效率新紀錄,每年減少碳排放超過75萬噸。


很高興代表項目聯合體領到這個獎項,這個項目也是我們在冶金鋼鐵行業、流程製造業數字化升級的重要實踐成果之一,GSMA對於武鋼—5G全連接智慧鋼鐵工廠項目的肯定和認可也將成為我們繼續前進的動力。 中興通訊副總裁李曉彤表示, 在武鋼有限園區內高溫、電磁干擾環境中應用的5G工業現場網端到端解決方案,已具備了與工業以太網相同的網絡能力,還具有部署靈活、接入便捷等優勢。未來,以中國寶武 四有 四化 為方向指引,中興通訊攜手更多的行業合作夥伴,加速推進數實融合,助推鋼鐵行業數字化改造和智能化升級。 

全球移動大獎(GLOMO)是移動通信行業權威組織GSMA在1996年創辦,2024由全球240多位分析師、媒體及業內專家組成評委團,是最具權威的通信業獎項,被譽為移動通信產業的奧斯卡,旨在表彰在快速增長的移動行業推動創新並展現出卓越成就的個人和公司。 

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: ZTE.press.release@zte.com.cn 

Information Provided by PR Newswire [Disclaimer]
08:00
Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Rα/TSLP bispecific antibody) in Australia

ROCKVILLE, Md. and SUZHOU, China, March 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been dosed in Australia in a first-in-human (FIH) phase 1 clinical trial of IBI3002, a global first-in-class bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP).

This FIH study (NCT06213844) is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) (only in participants with asthma) of IBI3002 in healthy participants and participants with mild to moderate asthma, and to support further global clinical development of IBI3002.

IBI3002 is a humanized bispecific antibody targeting cell surface IL-4Rα and the alarmin cytokine TSLP, discovered and developed by Innovent for the treatment of inflammatory diseases, including asthma. IL-4 receptors mediate the IL-4 signaling (both type 1 and type 2) and the IL-13 signaling (type 2). Both cytokine signaling pathways play key roles in the pathophysiology of type 2 (T2) inflammatory disorders1. TSLP is an epithelial cell-derived alarmin cytokine and triggers both T2 and non-T2 inflammation in asthma2.

IBI3002 has high-efficient dual-blocking function on both IL-4Rα and TSLP. In-vitro assays have shown superiority over the marketed monoclonal antibodies to respective target. By targeting both IL-4Rα and TSLP, IBI3002 is hypothesized to have potential effect in suppressing T2 and non-T2 inflammation. The potential synergistic effect in suppressing T2 inflammation is believed to be the basis of its superior efficacy in the treatment of T2 inflammatory disorders.

Dr. Lei Qian, Vice President of Clinical Development at Innovent, stated, "In the last few decades, knowledge about both pathophysiological mechanisms, clinical phenotypes and therapeutic options for asthma have significantly increased. In particular, the introduction of biologics for severe asthma paved the way to a true revolution in the field of asthma management, by potentially allowing a precision medicine approach. Targeting specific steps of the immune-inflammatory cascade through highly selective drugs represents a true revolution in the field of severe asthma management, and brings with it the potential of achieving optimal disease control in different severe asthma inflammatory phenotypes. We are looking forward to the development of this molecule in asthma and other inflammatory diseases."

About Asthma

Asthma is a heterogeneous disease driven by multiple immune cells, cytokines and inflammatory mediators, affecting all age groups. Characterized by variable symptoms of wheeze, shortness of breath, cough, and chest tightness, asthma is associated with chronic airway inflammation, reversible airflow limitation, and airway hyperresponsiveness3. According to the 2015 Global Burden of Disease (GBD) study, about 358 million people are suffering from asthma4. Asthma can be broadly classified as eosinophilic or non-eosinophilic on the basis of airway or peripheral blood cellular profiles. Eosinophilic inflammation is driven predominantly by T2 inflammation, including T-helper cells type 2 and group 2 innate lymphoid cells5. Compared with eosinophilic asthma, non-eosinophilic asthma is poorly understood6. Up to 10% of adults and 2.5% of children with asthma have severe asthma7. Patients with severe asthma have persistent symptoms or frequent exacerbations that require repetitive systemic glucocorticoid bursts or maintenance, despite adequate treatment with high-dose inhaled treatments8. In these patients, add-on treatment, which may include biologic therapies, is needed to reduce the disease burden2,3.

About IBI3002

IBI3002 is a global first-in-class bispecific antibody targeting cell surface IL-4Rα and the alarmin cytokine TSLP. It has high-efficient dual-blocking function on both IL-4Rα and TSLP. In-vitro assays have shown superiority over the marketed monoclonal antibodies to respective targets. By simultaneously targeting IL-4Rα and TSLP, IBI3002 has the potential of treating several inflammatory disorders, including asthma.

IL-4 is a central mediator of type 2 lymphocyte cell differentiation; it induces the production of type 2 associated cytokines such as IL-5, IL-9, IL-13, and/or type 2 related chemokines as thymus and activation-regulated chemokine (TARC/CCL17) and eotaxins-3. IL-4 involved in B cells regulated isotype class switching to produce serum IgE, and the eosinophils recruitment through IL-5 releasement. Although IL-13 displays some redundancies in these pro-inflammatory processes, it has additional roles in mediating goblet cell hyperplasia, mucus production, smooth muscle contractility, and airway hyperresponsiveness. Together, IL-4 and IL-13 play critical roles in T2 inflammation1.

TSLP is an epithelial cell-derived alarmin cytokine that occupies an upstream position in the T2 inflammation induction and Th2 cells differentiation and maturation via IL-4, IL-5 and IL-13 production. TSLP is also believed to be a trigger of non-T2 inflammation in asthma 2.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable illnesses. Its pioneering therapies to treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 4 assets in Phase III or pivotal clinical trials and 20 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

References: 

1.        Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production[J]. Cytokine, 2015, 75(1): 14-24.

2.        Brusselle G G, Koppelman G H. Biologic therapies for severe asthma[J]. New England Journal of Medicine, 2022, 386(2): 157-171.

3.        Global Initiative for Asthma. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. 2023.

4.        GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet Respir Med. 2017 Oct;5(10 ):e30]. Lancet Respir Med. 2017;5(9):691-706.

5.        Gans MD, Gavrilova T. Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes. Paediatr Respir Rev. 2020;36:118-127.

6.        Israel E, Reddel H K. Severe and difficult-to-treat asthma in adults[J]. New England Journal of Medicine, 2017, 377(10): 965-976.

7.        Settipane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol 2019; 123(6): 564-572.e3.

8.        Caminati M, Vaia R, Furci F, Guarnieri G, Senna G. Uncontrolled Asthma: Unmet Needs in the Management of Patients. J Asthma Allergy. 2021;14:457-466.

Information Provided by PR Newswire [Disclaimer]
08:00
信達生物宣佈IBI3002(抗IL-4Rα/TSLP雙特異性抗體)臨床I期研究在澳大利亞完成首例受試者給藥

美國羅克維爾和中國蘇州2024年3月1日 /美通社/ -- 信達生物製藥集團(香港聯交所股票代碼:01801),一家致力於研發、生產和銷售腫瘤、自身免疫、代謝及心血管、眼科等重大疾病領域創新藥物的生物製藥公司,宣佈IBI3002的首次人體(FIH)臨床I期研究已在澳大利亞完成首例受試者給藥。IBI3002是一種全球首創(first-in-class)的靶向白細胞介素4受體α(IL-4Rα)和胸腺基質淋巴細胞生成素(TSLP)的雙特異性抗體。

本項FIH研究(NCT06213844)是一項隨機、雙盲、安慰劑對照、單次給藥劑量遞增(SAD)研究,旨在評估IBI3002在健康受試者和輕中度哮喘受試者中的安全性、耐受性、藥代動力學(PK)和藥效學(PD,僅在哮喘受試者中),以支持IBI3002後續全球臨床開發。

IBI3002是信達生物自主研發的人源化雙特異性抗體,靶向細胞表面IL-4Rα和警報素細胞因子TSLP,用於治療包括哮喘在內的炎症性疾病。IL-4受體介導了IL-4信號通路(1型和2型)和IL-13信號通路(2型),兩種細胞因子信號通路在2型炎症性疾病的病理生理學中均起關鍵作用[1]。TSLP是一種上皮細胞來源的警報素細胞因子,可觸發哮喘中的2型和非2型炎症[2]

IBI3002具有高效的IL-4Rα和TSLP共同阻斷功能。體外功能學實驗顯示比同靶點的已上市單克隆抗體更優。通過同時靶向IL-4Rα和TSLP,IBI3002具有抑制2型和非2型炎症的潛力,在抑制2型炎症方面具有潛在的協同作用,有望在治療2型炎症性疾病中展現優效性。

信達生物製藥集團臨床開發副總裁錢鐳博士表示:「在過去的幾十年裡,醫療界對哮喘的病理生理機制/表型和治療選擇的認知有了顯著增加,特別是通過引入生物制劑治療重度哮喘這一精準治療的策略,為哮喘管理帶來革命性的變革。高選擇性藥物通過靶向免疫炎症級聯的特定步驟,有潛力進一步突破廣大嚴重哮喘患者的治療局限,並有望在多種重度哮喘炎症表型中實現最佳疾病控制;同時,我們也期待推進該分子未來在哮喘和其他多種炎症性疾病中的進一步開發。」

關於哮喘

哮喘是一種由多種免疫細胞、細胞因子及炎症介質介導,累及全年齡段人群的異質性疾病,以喘息、氣促、咳嗽和胸悶等多種症狀為特徵,與慢性氣道炎症、可變的氣流受限和氣道高反應性相關[3]。根據2015年全球疾病負擔(GBD)研究,約有3.58億人患有哮喘[4]。根據氣道或外周血細胞特徵,哮喘可大致分為嗜酸性粒細胞性和非嗜酸性粒細胞性哮喘。嗜酸性粒細胞炎症主要由2型炎症驅動,包括2型輔助T細胞和2型固有淋巴細胞[5]。與嗜酸性粒細胞性哮喘相比,對於非嗜酸性粒細胞性哮喘的瞭解仍不充分[6]。高達10%的成人哮喘患者和2.5%的兒童哮喘患者患有重度哮喘[7]。儘管接受了足夠的大劑量吸入治療,重度哮喘患者仍存在症狀持續或頻繁急性加重,需要反覆系統性糖皮質激素短期或維持治療[8]。在這些患者中,需要給予額外治療(可能包括生物制劑)以減輕疾病負擔[2,3]

關於IBI3002

IBI3002是一款全球首創靶向細胞表面IL-4Rα和警報素細胞因子TSLP的雙特異性抗體。該分子具有高效的IL-4Rα和TSLP共同阻斷功能。體外功能學實驗顯示比同靶點的已上市單克隆抗體更優。通過同時靶向IL-4Rα和TSLP,IBI3002具有治療包括哮喘在內多種炎症性疾病的潛力。

IL-4是2型淋巴細胞分化的中心介質;它誘導產生2型相關細胞因子,如IL-5、IL-9、IL-13和/或2型相關趨化因子,如胸腺和活化調節趨化因子(TARC/CCL17)和嗜酸性粒細胞趨化因子-3。IL-4參與調節B細胞的同種型類別轉換以產生血清IgE,並通過釋放IL-5招募嗜酸性粒細胞。儘管IL-13在這些促炎過程中顯示出一些冗余性,但它在介導杯狀細胞增生、粘液產生、平滑肌收縮性和氣道高反應性方面具有額外的作用。總的來說,IL-4和IL-13共同在2型炎症中起關鍵作用[1]

TSLP是一種上皮細胞來源的警報素細胞因子,它在2型炎症誘導和通過IL-4、IL-5和IL-13產生的Th2細胞分化與成熟中佔據上游位置。TSLP也被認為是哮喘中非2型炎症的觸發因素[2]

關於信達生物

「始於信,達於行」,開發出老百姓用得起的高質量生物藥,是信達生物的使命和目標。信達生物成立於2011年,致力於開發、生產和銷售腫瘤、代謝及心血管、自身免疫、眼科等重大疾病領域的創新藥物。公司已有10款產品獲得批准上市,同時還有3個品種在NMPA審評中,4個新藥分子進入III期或關鍵性臨床研究,另外還有19個新藥品種已進入臨床研究。公司與海內外藥企深入合作加速藥物創新,與禮來、羅氏、賽諾菲、Adimab、Incyte和MD Anderson 癌症中心等國際合作方達成30多項戰略合作。

信達生物在不斷開發創新藥物、謀求自身發展的同時,始終心懷科學善念,堅守「以患者為中心」,心繫患者並關注患者家庭,積極履行社會責任。信達生物希望和大家一起努力,提高中國生物製藥產業的發展水平,以滿足百姓用藥可及性和人民對生命健康美好願望的追求。

詳情請訪問公司網站:www.innoventbio.com或公司領英賬號www.linkedin.com/company/innovent-biologics/

聲明:信達不推薦任何未獲批的藥品/適應症使用。

前瞻性聲明

本新聞稿所發佈的信息中可能會包含某些前瞻性表述。這些表述本質上具有相當風險和不確定性。在使用「預期」、「相信」、「預測」、「期望」、「打算」及其他類似詞語進行表述時,凡與本公司有關的,目的均是要指明其屬前瞻性表述。本公司並無義務不斷地更新這些預測性陳述。

這些前瞻性表述乃基於本公司管理層在做出表述時對未來事務的現有看法、假設、期望、估計、預測和理解。這些表述並非對未來發展的保證,會受到風險、不確性及其他因素的影響,有些乃超出本公司的控制範圍,難以預計。因此,受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展的影響,實際結果可能會與前瞻性表述所含資料有較大差別。

參考文獻:

1. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production[J]. Cytokine, 2015, 75(1): 14-24.

2. Brusselle G G, Koppelman G H. Biologic therapies for severe asthma[J]. New England Journal of Medicine, 2022, 386(2): 157-171.

3. Global Initiative for Asthma. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. 2023.

4. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet Respir Med. 2017 Oct;5(10 ):e30]. Lancet Respir Med. 2017;5(9):691-706.

5. Gans MD, Gavrilova T. Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes. Paediatr Respir Rev. 2020;36:118-127.

6. Israel E, Reddel H K. Severe and difficult-to-treat asthma in adults[J]. New England Journal of Medicine, 2017, 377(10): 965-976.

7. Settipane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol 2019; 123(6): 564-572.e3.

8. Caminati M, Vaia R, Furci F, Guarnieri G, Senna G. Uncontrolled Asthma: Unmet Needs in the Management of Patients. J Asthma Allergy. 2021;14:457-466.

 

Information Provided by PR Newswire [Disclaimer]
2024-02-29
17:48
MINISO Group Will Report December Quarter 2023 Financial Results on March 12, 2024

GUANGZHOU, China, Feb. 29, 2024 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a global value retailer offering a variety of trendy lifestyle products featuring IP design, today announced that it plans to release its December quarter 2023 financial results before the U.S. market opens on Tuesday, March 12, 2024.

The Company's management will hold an earnings conference call at 5:00 A.M. Eastern Time on Tuesday, March 12, 2024 (5:00 P.M. Beijing Time on the same day) to discuss the financial results. The conference call can be accessed by the following Zoom link or dialing the following numbers:

Access 1

Join Zoom meeting.

Zoom link: https://us06web.zoom.us/j/88486834973?pwd=hLtL1nO9NpERFFfgHFZVIZKCbqrlbB.1
Meeting Number: 884 8683 4973
Meeting Passcode: 9896

Access 2

Listeners may access the call by dialing the following numbers by using the same meeting number and passcode with access 1.

United States:                                       

+1 213 338 8477 (or +1 646 518 9805)

Hong Kong, China:                             

+852 5803 3730 (or +852 5803 3731)

United Kingdom:                                 

+44 203 481 5237 (or +44 131 460 1196)

France:                                                  

+33 1 7037 9729 (or +33 1 7037 2246)

Singapore:                                             

+65 3158 7288 (or +65 3165 1065)

Canada:                                                

+1 438 809 7799 (or +1 204 272 7920)

Access 3

Listeners can also access the meeting through the Company's investor relations website at https://ir.miniso.com/.

The replay will be available approximately two hours after the conclusion of the live event at the Company's investor relations website at https://ir.miniso.com/.

About MINISO Group

MINISO Group is a global value retailer offering a variety of trendy lifestyle products featuring IP design. The Company serves consumers primarily through its large network of MINISO stores, and promotes a relaxing, treasure-hunting and engaging shopping experience full of delightful surprises that appeals to all demographics. Aesthetically pleasing design, quality and affordability are at the core of every product in MINISO's wide product portfolio, and the Company continually and frequently rolls out products with these qualities. Since the opening of its first store in China in 2013, the Company has built its flagship brand "MINISO" as a globally recognized retail brand and established a massive store network worldwide. For more information, please visit https://ir.miniso.com/.

Investor Relations Contact
Raine Hu
MINISO Group Holding Limited
Email: ir@miniso.com
Phone: +86 (20) 36228788 Ext.8039

Information Provided by PR Newswire [Disclaimer]
17:36
中興通訊攜手德國O2探索零碳站點建設,為通信未來注入綠色創新

西班牙巴塞羅那2024年2月29日 /美通社/ -- 日前,中興通訊采用太陽能、甲醇制氫燃料電池和智能儲能的創新綠色供電解決方案成功為德國O2建設了一座通信站點,在探索零碳站點方面取得了積極的進展。這是德國O2首次在商用中采用這一綠色方案,在邊遠通信站點展現綠色創新力量。

中興通訊攜手德國O2探索零碳站點建設,為通信未來注入綠色創新
中興通訊攜手德國O2探索零碳站點建設,為通信未來注入綠色創新

在全球綠色低碳理念日益盛行的今天,德國政府和企業積極響應,踐行可持續發展理念。身為德國知名通信運營商,O2公司宣布計劃新建數千個邊遠通信站點,旨在為偏遠地區居民提供高質量、高穩定性的通信服務,讓他們同樣能夠享受到高速網絡帶來的便捷。然而,部分偏遠地區市電接入存在施工周期長、成本高昂的問題,給項目執行帶來了極大的挑戰。為解決這一難題,中興通訊與德國O2展開了深度合作,充分考慮綠色、安全、可持續等多方面因素,共同探索,創新實現了適合於當地情況的新能源、低排放站點解決方案。

首先,站點供電以太陽能發電為主,當在冬季或雨水季節光照弱時由甲醇制氫燃料電池作為發電補充,從而實現了100%的供電可用性,有效保障通信服務的穩定運行。這意味著偏遠地區的居民不再需要擔心通信中斷,能夠與全球保持暢通聯系。

其次,采用太陽能和甲醇制氫燃料電池的組合,最終產物只有水和少量二氧化碳,從根本上降低了碳排放問題。這一極致綠色的能源解決方案不僅對環境友好,也符合德國政府和企業對可持續發展的高標准要求。

此外,甲醇制氫在模塊內完成,避免了氫氣存儲和運輸中的洩露和爆炸風險,相較傳統氫燃料電池更為安全和環保。這為O2公司提供了可靠且安全的能源供應,使其能夠更專注於提供卓越的通信服務。

中興通訊的能源智能運營系統iEnergy能夠實時監控站點的設備狀態、電力供應和能源利用情況等關鍵數據,實現了精細化管理和智能運維。該系統幫助德國O2進一步提高站點運維效率,降低了運營成本。

這一成功案例為德國O2解決邊遠地區站點供電現狀提供了創新思路,也為其在後續類似應用場景積累了寶貴經驗。同時,該解決方案可推廣至其他歐洲運營商,為整個行業的碳中和目標貢獻新的力量。

中興通訊一直堅信,持續創新是踐行綠色低碳理念的關鍵。未來,中興通訊將繼續深化與全球客戶的合作,共同探索綠色轉型之道,致力於讓世界因為我們的努力而更加美好。

MEDIA INQUIRIES:
ZTE Corporation
Communications
Email: ZTE.press.release@zte.com.cn

Information Provided by PR Newswire [Disclaimer]
16:45
閱文集團將於2024年3月18日公佈2023年全年業績

業績電話會議將於2024318日星期

晚上8:00(香港時間)/上8:00(美國東部時間)舉行

香港2024年2月29日 /美通社/ -- 中國領先的在線閱讀和IP培育平台閱文集團(「閱文」或「公司」,股份代號:0772.HK)宣佈將於2024318日星期公佈2023年全年業績。

閱文集團管理層將召開電話會議,討論期內公司財務和業務狀況。電話會議的網絡直播可在公司投資者關係網站http://ir.yuewen.com同步收聽。

電話會議和網絡直播詳情如下:

時間:晚上8:00(香港時間)/上午8:00(美國東部時間)
語言:英語
網絡直播和重播:https://ir-api.yuewen.com/calendar/WebcastsCalls/2023FY

如與會者希望使用電話號碼撥入會議,請使用下面提供的鏈接提前註冊,並在會議開始前10分鐘撥入。您的撥打號碼密碼和唯一的訪問PIN將會在註冊時提供。

預註冊鏈接:https://s1.c-conf.com/diamondpass/10037200-lo01q3.html

電話會議的重播將於會議結束後啟用,有效時間至2024年3月25日:

美國:+1 855 883 1031
香港:800 930 639
新加坡:800 101 3223
國際:+61 7 3107 6325
密碼:10037200

如有垂詢,敬請聯絡:

投資者/分析師聯絡:
Maggie Zhou
電話:+8621 6187 0500轉80605
電郵:IR@yuewen.com

媒體聯絡:
Vivian Wang
電話:+852 2232 3978
電郵:vwang@Christensenir.com

Information Provided by PR Newswire [Disclaimer]